GYRE
Price:
$7.69
Market Cap:
$698.60M
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis asso...[Read more]
Industry
Biotechnology
IPO Date
2006-04-12
Stock Exchange
NASDAQ
Ticker
GYRE
According to Gyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.19. This represents a change of 33.84% compared to the average of 4.63 of the last 4 quarters.
The mean historical Current Ratio of Gyre Therapeutics, Inc. over the last ten years is 5.60. The current 6.19 Current Ratio has changed 10.95% with respect to the historical average. Over the past ten years (40 quarters), GYRE's Current Ratio was at its highest in in the June 2018 quarter at 56.98. The Current Ratio was at its lowest in in the September 2016 quarter at 1.59.
Average
5.60
Median
3.48
Minimum
1.71
Maximum
25.83
Discovering the peaks and valleys of Gyre Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 477.09%
Maximum Annual Current Ratio = 25.83
Minimum Annual Increase = -95.10%
Minimum Annual Current Ratio = 1.71
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 3.32 | 16.30% |
| 2023 | 2.85 | -29.63% |
| 2022 | 4.06 | 11.61% |
| 2021 | 3.63 | -27.75% |
| 2020 | 5.03 | 51.30% |
| 2019 | 3.32 | -87.13% |
| 2018 | 25.83 | 477.09% |
| 2017 | 4.48 | 161.98% |
| 2016 | 1.71 | -6.12% |
| 2015 | 1.82 | -95.10% |
The current Current Ratio of Gyre Therapeutics, Inc. (GYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.41
5-year avg
3.78
10-year avg
5.60
Gyre Therapeutics, Inc.’s Current Ratio is less than Anavex Life Sciences Corp. (13.41), less than Erasca, Inc. (11.04), greater than CytomX Therapeutics, Inc. (3.64), less than MBX Biosciences, Inc. Common Stock (32.95), less than MoonLake Immunotherapeutics (16.65), less than Astria Therapeutics, Inc. (14.89), less than Keros Therapeutics, Inc. (29.86), greater than MeiraGTx Holdings plc (0.22), greater than Iovance Biotherapeutics, Inc. (3.27), less than ArriVent BioPharma, Inc. Common Stock (12.74),
| Company | Current Ratio | Market cap |
|---|---|---|
| 13.41 | $359.17M | |
| 11.04 | $1.02B | |
| 3.64 | $710.51M | |
| 32.95 | $1.00B | |
| 16.65 | $942.76M | |
| 14.89 | $737.54M | |
| 29.86 | $871.17M | |
| 0.22 | $717.17M | |
| 3.27 | $729.72M | |
| 12.74 | $1.01B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Gyre Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Gyre Therapeutics, Inc. (GYRE)?
What is the highest Current Ratio for Gyre Therapeutics, Inc. (GYRE)?
What is the 3-year average Current Ratio for Gyre Therapeutics, Inc. (GYRE)?
What is the 5-year average Current Ratio for Gyre Therapeutics, Inc. (GYRE)?
How does the current Current Ratio for Gyre Therapeutics, Inc. (GYRE) compare to its historical average?